Palogic Value Management L.P. Makes New $2.26 Million Investment in Health Catalyst, Inc. (NASDAQ:HCAT)

Palogic Value Management L.P. bought a new stake in Health Catalyst, Inc. (NASDAQ:HCAT - Free Report) in the fourth quarter, according to its most recent Form 13F filing with the SEC. The institutional investor bought 320,000 shares of the company's stock, valued at approximately $2,262,000. Palogic Value Management L.P. owned 0.53% of Health Catalyst as of its most recent SEC filing.

A number of other institutional investors also recently bought and sold shares of the business. Fred Alger Management LLC purchased a new position in shares of Health Catalyst during the 3rd quarter worth about $6,858,000. Portolan Capital Management LLC bought a new position in Health Catalyst during the third quarter worth $5,402,000. Raymond James Financial Inc. bought a new position in shares of Health Catalyst during the fourth quarter valued at approximately $2,044,000. Martin & Co. Inc. TN lifted its position in Health Catalyst by 80.0% in the 4th quarter. Martin & Co. Inc. TN now owns 490,998 shares of the company's stock valued at $3,471,000 after purchasing an additional 218,293 shares during the last quarter. Finally, Point72 Asset Management L.P. raised its stake in shares of Health Catalyst by 69.4% during the third quarter. Point72 Asset Management L.P. now owns 516,934 shares of the company's stock valued at $4,208,000 after purchasing an additional 211,805 shares in the last quarter. 85.00% of the stock is currently owned by institutional investors and hedge funds.

Insider Activity at Health Catalyst

In other news, General Counsel Benjamin Landry sold 13,827 shares of the firm's stock in a transaction that occurred on Thursday, March 6th. The stock was sold at an average price of $4.55, for a total value of $62,912.85. Following the transaction, the general counsel now owns 160,437 shares in the company, valued at $729,988.35. This trade represents a 7.93 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Also, COO Daniel Lesueur sold 5,209 shares of the stock in a transaction dated Monday, January 6th. The shares were sold at an average price of $7.51, for a total transaction of $39,119.59. Following the completion of the sale, the chief operating officer now owns 91,253 shares of the company's stock, valued at approximately $685,310.03. This trade represents a 5.40 % decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 61,030 shares of company stock worth $330,757 in the last quarter. 2.50% of the stock is owned by insiders.

Analyst Ratings Changes

A number of research firms recently commented on HCAT. KeyCorp raised shares of Health Catalyst from a "sector weight" rating to an "overweight" rating and set a $9.00 price objective for the company in a research note on Wednesday, January 8th. Wells Fargo & Company cut their target price on Health Catalyst from $13.00 to $10.00 and set an "overweight" rating for the company in a research note on Tuesday, January 21st. Citigroup dropped their price objective on shares of Health Catalyst from $10.50 to $10.00 and set a "buy" rating for the company in a report on Friday, January 10th. Piper Sandler dropped their target price on Health Catalyst from $12.00 to $8.00 and set an "overweight" rating for the company in a research report on Tuesday, February 11th. Finally, Canaccord Genuity Group reduced their target price on Health Catalyst from $11.00 to $10.00 and set a "buy" rating on the stock in a report on Tuesday, January 21st. Three equities research analysts have rated the stock with a hold rating and eight have given a buy rating to the company's stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of "Moderate Buy" and an average target price of $9.27.

Health Catalyst Price Performance

Shares of Health Catalyst stock traded up $0.01 during midday trading on Tuesday, hitting $4.47. 468,500 shares of the company traded hands, compared to its average volume of 601,323. Health Catalyst, Inc. has a 12 month low of $3.76 and a 12 month high of $9.24. The firm's fifty day moving average price is $5.12 and its 200-day moving average price is $6.94. The company has a debt-to-equity ratio of 0.32, a quick ratio of 1.41 and a current ratio of 1.41. The stock has a market cap of $313.84 million, a price-to-earnings ratio of -3.31 and a beta of 1.41.

Health Catalyst Profile

Health Catalyst, Inc provides data and analytics technology and services to healthcare organizations in the United States. It operates in two segments, Technology and Professional Services. The company provides data operating system data platform which provides clients single comprehensive environment to integrate and organize data from their disparate software systems; and analytics applications, a software analytics applications build for data platform to analyze clients face across clinical and quality, population health, and financial and operational use cases.